Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
22.51
-1.83 (-7.52%)
At close: Oct 13, 2026, 4:00 PM EDT
22.51
0.00 (0.00%)
After-hours: Oct 13, 2026, 4:10 PM EDT
Arcus Biosciences Revenue
Arcus Biosciences had revenue of $41.00M in the quarter ending June 30, 2026, a decrease of -74.38%. This brings the company's revenue in the last twelve months to $117.00M, down -55.34% year-over-year. In the year 2025, Arcus Biosciences had annual revenue of $247.00M, down -4.26%. That makes Arcus Biosciences the 21,450th largest company in the world by revenue and 3,194th in the United States.
Revenue (ttm)
$117.00M
Revenue Growth
-55.34%
P/S Ratio
24.50
Revenue / Employee
$194,676
Employees
601
Market Cap
2.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 247.00M | -11.00M | -4.26% |
| Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
| Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
| Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
| Dec 31, 2021 | 383.00M | 305.00M | 391.03% |
| Dec 31, 2020 | 78.00M | 63.00M | 420.00% |
| Dec 31, 2019 | 15.00M | 6.65M | 79.58% |
| Dec 31, 2018 | 8.35M | 6.94M | 491.15% |
| Dec 31, 2017 | 1.41M | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Acadia Pharmaceuticals | 1.14B |
| Tarsus Pharmaceuticals | 606.33M |
| Arcutis Biotherapeutics | 463.98M |
| Zai Lab | 449.61M |
| Precigen | 85.72M |
| Denali Therapeutics | 3.60M |
RCUS News
- 4 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 21 days ago - Arcus Biosciences to host investor event on casdatifan data - TheFly
- 21 days ago - Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy - Business Wire
- 27 days ago - Arcus Biosciences initiated with a Buy at TD Cowen - TheFly
- 4 weeks ago - Arcus Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - Arcus Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Arcus Biosciences Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 5 weeks ago - Arcus Biosciences price target raised to $40 from $35 at Truist - TheFly